🟢 80/100

This product is generally safe

  • Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)
  • 50% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)

Label Data

1 Tablet(s) Serving Size
50 Servings
Single Vitamin and Mineral Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

100 mg (625% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 2.9× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 100mg UL 35mg
Calcium
160 mg (12% DV)

Other Ingredients

Cellulose Croscarmellose Sodium Maltodextrin Silicon Dioxide Stearic Acid

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Directions: As a vitamin supplement, adults take on (1) tablet daily with any meal or as directed by a healthcare provider. Do not exceed recommended dosage. Individual results may vary.

⚠️ Warnings & Precautions

Keep out of reach of children.

Do not use if product appears to be tampered with.

Warning: Consult a healthcare provider prior to use if pregnant, nursing, on medications, have a medical condition or are planning a medical procedure.

Stop use and contact a physician if adverse reaction occur.

🧪 Formulation Notes

Energy & Circulatory Support

No added sugar, yeast, preservatives, artificial flavors or colors.

Gluten Free

Additional Information

Guaranteed Quality Laboratory Tested

50268-582-15 50 Tablets (5 x 10) Unit Dose

Store at room temperature.

Product Details

UPC / SKU 5026858215
DSLD Entry Date 2022-08-23
Product Type Single Vitamin and Mineral
Form Tablet or Pill
Brand AvPAK
DSLD ID 271383
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →